ArticleIranian journal of pathology2020
Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study.
Article in Iranian journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Artificial intelligence in breast surgery: Current applications, challenges, and future perspectives.The Journal of international medical research · 2026Review
- Peripheral blood tumor marker levels can indicate the location of lung cancer metastasis.Oncology letters · 2025Article
- ERK-driven autophagy enhances synergy of eribulin and cisplatin in triple-negative breast cancer.Oncology letters · 2025Article
- Serum Cytokeratin 18 as a Potential Early Marker for Chemotherapy Response in Breast Cancer Patients: A Prospective Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines.Data in brief · 2023Article
- The Role of Nomogram Based on the Combination of Ultrasound Parameters and Clinical Indicators in the Degree of Pathological Remission of Breast Cancer.Journal of oncology · 2023Article
- Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Review
- Pure small cell neuroendocrine carcinoma of urinary bladder: A case report.Clinical case reports · 2022Article
- Endometrial adenocarcinoma with bone metastasis: A case report.Clinical case reports · 2022Article
- Tongue metastasis originated from esophageal squamous cell carcinoma: A case report.Clinical case reports · 2022Article
- Case series on patients with primary central nervous system lymphoma: From clinical presentations to outcomes.Clinical case reports · 2022Article
- The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage.Frontiers in oncology · 2022Article
- Prediction of Survival Rate and Chemotherapy Effect by an Immune Score Model in Colorectal Cancer.BioMed research international · 2022Article
- High-Intensity Focused Ultrasound Enhanced Anti-Tumor Activities of Paclitaxel in Breast Cancer in vitro and in vivo.Cancer management and research · 2022Article
- Massive pericardial effusion as the first manifestation of childhood non-Hodgkin's lymphoma: A case report.Clinical case reports · 2021Article
- A case report of prostate adenocarcinoma with leptomeningeal carcinomatosis and intracerebral metastasis.Clinical case reports · 2021Article
- A case report of endometrial adenocarcinoma with leptomeningeal metastases.Clinical case reports · 2021Article
- A Narrative Review of Ultrasound Technologies for the Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer.Cancer management and research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
objectivePrediction of response to neoadjuvant treatment is an important part of treatment of patients with breast cancer. This study aimed to assess changes in serum levels of Cytokeratin 18 during neoadjuvant chemotherapy in patients with locally advanced breast cancer and its association with neoadjuvant treatments.
methodsThis research was performed on newly diagnosed breast cancer patients referred to Omid Radiotherapy Center and radiotherapy and oncology departments of Emam Reza and Ghaem hospitals, in Mashhad, Iran. Serum levels of M30 and M65 fragments of Cytokeratin 18 were measured before and 24 hours after the first course of neoadjuvant chemotherapy. Changes in serum levels of Cytokeratin 18 and its fragments and their correlation with pathologic response were analyzed.
resultsPre- and post-chemotherapy levels of M30 were respectively 223.9±18.94 and 250.7±23.92 U/L (
conclusionOur findings showed statistically insignificant changes in the level of Caspase-cleaved- (M30) and uncleaved- (M65) cytokeratin 18 fragments (apoptotic and necrotic indicators, respectively) during neoadjuvant chemotherapy in patients with breast cancer. There was no notable relationship between tumor-related factors and either baseline levels or serum changes of CK18 fragments. Also, there was no correlation between M30/M65 level and pathologic response to neoadjuvant chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.